Children’s analgesic and antipyretic drug :: Consumers survey results of for 2 quarter of 2024

Consumers survey results of for 2 quarter of 2024 in category

Cold and Flu / Children’s analgesic and antipyretic drug

The annual ratings by results of Consumers survey calculated as average arithmetic mean rank, obtained in each of 4 quarters of year.

	I quarter (january—march)
	II quarter (april—june)
	III quarter (july—september)
	IV quarter (october—december)

1.	Ліки ведмедика БО (Парацетамол для дітей) (Борщагівський ХФЗ)	66.67%	5

2.	Ibufen (Polpharma S.A.)	33.33%	2.50

2.	Malipin (Vishpha \| Фармацевтична фабрика Vishpha)	33.33%	2.50

2.	Nurofen for children (Reckitt Benckiser)	33.33%	2.50

–.	Efferalgan for children (Bristol-Myers Squibb)	0.00%	0

–.	Panadol Baby and Infant (GlaxoSmithKline)	0.00%	0

–.	Rapidol (Actavis)	0.00%	0

–.	Ібунорм Бебі (Pharmaceutical company “Zdorovya”)	0.00%	0

–.	Мілістан (Mili Healthcare)	0.00%	0

–.	Фервекс для дітей (Bristol-Myers Squibb)	0.00%	0

–.	Хелпекс Антиколд Нео для дітей (Movi Health GmbH)	0.00%	0

This rating reflects the current interim results of the study of public opinion as on 11/24/2024 16:11:17 and it’s not yet final.

Strictly prohibited any use and reproduction of unfinished voting results without link to the source, without clear explanation of the methodology of the “Favorites of Success” Contest and without mandatory notes that poll is still continues and this result is not yet final.